Anzeige
Mehr »
Samstag, 16.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
296 Leser
Artikel bewerten:
(1)

Beacon Therapeutics (USA), Inc.: Beacon Therapeutics Strengthens Leadership Team with the Appointment of Dr. Daniel Chung as Chief Medical Officer

Dr. Chung brings over three decades of experience spanning clinical ophthalmology, academic research and gene therapy development

LONDON and CAMBRIDGE, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited ('Beacon Therapeutics' or 'the Company'), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announces the appointment of Dr. Daniel Chung as Chief Medical Officer, effective immediately.

Dr. Chung brings a wealth of experience in clinical ophthalmology, academic research and gene therapy development spanning three decades. Most recently, he served as Chief Medical Officer at SparingVision, a clinical-stage genomic medicine company. Previously, Dr. Chung served as Ophthalmology Therapeutic Area Leader at Spark Therapeutics, where he played an instrumental role in the development of Luxturna® (voretigene neparvovec), the first gene therapy approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for use in a blinding genetic disease. He also served as Senior Investigator at the FM Kirby Center for Molecular Ophthalmology at the University of Pennsylvania Perelman School of Medicine and as the Sub-Principal Investigator/Scientific Advisor on the RPE65 gene therapy study team at the Children's Hospital of Philadelphia (CHOP).

"We are thrilled to welcome Dan to our leadership team," saidLance Baldo, M.D., Chief Executive Officer of Beacon Therapeutics. "He brings deep clinical and translational expertise in developing gene therapies for retinal diseases and has demonstrated an unwavering commitment to patients and the clinical community supporting blinding diseases. His appointment comes at a critical time for Beacon as we approach the completion of enrollment of our registrational Phase 2/3 VISTA trial."

"Beacon Therapeutics is making great progress, and I look forward to being part of an inspired team with its unique approach to advancing gene therapy to address rare and prevalent retinal diseases," added Dr. Chung. "X-linked retinitis pigmentosa is a devastating disease with no currently approved treatment. I am greatly encouraged by the data from the Phase 2 DAWN trial, and look forward to applying my expertise to advance laru-zova through the regulatory process, one step closer to approval, and potentially treating patients living with progressive vision loss."

Dr. Chung completed fellowships in pediatric ophthalmology and ocular genetics research at the Cole Eye Institute at the Cleveland Clinic, and in retinal gene therapy at the National Eye Institute, part of the U.S. National Institutes of Health. Prior to this, he completed his ophthalmology residency at Summa Health System in Akron, Ohio. He holds a B.S. in Biology and M.A. in Family Counseling from Eastern Nazarene College and a D.O. in Medicine from New York College of Osteopathic Medicine.

Beacon Therapeutics recently announcedpositive six-month interim safety and efficacy results from the Phase 2 DAWN trial of Beacon's lead program, laru-zova, in patients with X-linked retinitis pigmentosa (XLRP).

Contact:
info@beacontx.com

Media & Investors:
beacon@icrhealthcare.com

About Beacon Therapeutics
Beacon Therapeutics is a clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases. The Company has an established scientific foundation that includes a late-stage clinical development candidate to treat XLRP and two preclinical programs targeting dry age-related macular degeneration (AMD) and an inherited cone-rod dystrophy (CRD).

Beacon Therapeutics' investors include Syncona Limited, Forbion, Oxford Science Enterprises, TCGX and Advent Life Sciences, among others. Learn more about Beacon Therapeutics at beacontx.com.


© 2025 GlobeNewswire (Europe)
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.